| Purity: | 99% |
|---|---|
| Model Number: | 73963-72-1 |
| Brand Name: | NJBN STEROID |
| Grade Standard: | Medicine Grade |
| Type: | Anti-platelet And Anti-clotting drugs |
| Place of Origin: | China (Mainland) |
| EINECS No.: | 73963-72-1 |
| MF: | C20H27N5O2 |
| Other Names: | 6-[4-(1-CYCLOHEXYL-1H-TETRAZOL-5-YL)BUTOXY]-3,4-DIHYDRO-2(1H)-QUINOLIN |
| CAS No.: | 73963-72-1 |
| MW: | 369.46 |
| Sample: | Free |
| Market: | Worldwide |
Quick Details
Specifications
Anti-platelet And Anti-clotting drugs 73963-72-1 Cilostazol
_______________________________________________________________________________________________
Cilostazol
_______________________________________________________________________________________________
description of Cilostazol
Cilostazol is commonly used clinically anti-platelet and anti-clotting drugs. It belongs to a phosphodiesterase inhibitor and can inhibit the activity of phosphodiesterase of platelet and smooth muscle cells, leading to increase of the AMP concentration in platelets and vascular smooth muscle. It can significantly inhibit the platelet aggregation induced by various kinds of aggregation inducers, and can cause the dissociation of the aggregates. Its major metabolite, epoxide has a three to four fold activity of the prototype drug. It has significant antithrombotic effect on the brain circulation and peripheral circulatory disturbance caused by collagen, ADP, arachidonic acid and sodium laurate. Artery injection of this product can increase the blood flow rate with the strongest effect on the peripheral blood vessels but the weakest effect on the cerebral blood vessels.
_______________________________________________________________________________________________
COA
_______________________________________________________________________________________________
Application of Cilostazol
It can be used to alleviate the ischemic symptom such as ulcers, limb pain, cold sensation and intermittent claudication caused by chronic arterial occlusive disease. It can also be applied to the adjuvant treatment of atherosclerosis, arteritis, thromboangiitis obliterans, diabetes-induced ischemia of extremity and takayasu arteritis. Cilostazol also be used as a complementary therapy after surgical treatment to help alleviate the symptoms, improve the circulation and inhibiting thrombosis in transplanted blood vessel.
_______________________________________________________________________________________________
Cilostazol
| Synonyms | 6-[4-(1-CYCLOHEXYL-1H-TETRAZOL-5-YL)BUTOXY]-3,4-DIHYDRO-2(1H)-QUINOLINONE; 6-[4-(1-cyclohexyl-1h-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1h)-quinolinone additional name: 6-[4-(1-cyclohexyl-5-tetrazolyl)butoxy]-1,2,3,4-tetrahydro-2-oxoquinolinone; CILASTAZOL; CILOSTAZOL; CILOSTAZOLE; RETAL; OPC 13013; OPC 21 |
| CAS | 73963-72-1 |
| MF | C20H27N5O2 |
| MW |
369.46 |
| Purity | 99% |
| Categories |
Active-Pharmaceutical-Ingredients; Intermediates& Fine-Chemicals; Pharmaceuticals; API's; inhibitor; Cardiovascular APIs |
_______________________________________________________________________________________________
description of Cilostazol
Cilostazol is commonly used clinically anti-platelet and anti-clotting drugs. It belongs to a phosphodiesterase inhibitor and can inhibit the activity of phosphodiesterase of platelet and smooth muscle cells, leading to increase of the AMP concentration in platelets and vascular smooth muscle. It can significantly inhibit the platelet aggregation induced by various kinds of aggregation inducers, and can cause the dissociation of the aggregates. Its major metabolite, epoxide has a three to four fold activity of the prototype drug. It has significant antithrombotic effect on the brain circulation and peripheral circulatory disturbance caused by collagen, ADP, arachidonic acid and sodium laurate. Artery injection of this product can increase the blood flow rate with the strongest effect on the peripheral blood vessels but the weakest effect on the cerebral blood vessels.
_______________________________________________________________________________________________
COA
|
Items of analysis |
Specification |
Results |
|
Appearance |
White crystalline powder |
Confirms |
|
Melting point |
158-162℃ |
158-161℃ |
|
Dry weight loss |
≤0.3% |
≤0.27% |
|
Ash content |
≤0.1% |
0.09% |
|
Heavy metals |
≤10ppm |
10ppm |
|
Methanol |
≤0.1% |
0.08% |
|
Chloride |
≤0.02% |
0.015% |
|
Main impurity |
≤0.2% |
0.187% |
|
Total impurity |
≤0.5% |
≤0.5% |
|
Purity(HPLC) |
≥99% |
99.5% |
|
Conclusion |
Qualified |
|
_______________________________________________________________________________________________
Application of Cilostazol
It can be used to alleviate the ischemic symptom such as ulcers, limb pain, cold sensation and intermittent claudication caused by chronic arterial occlusive disease. It can also be applied to the adjuvant treatment of atherosclerosis, arteritis, thromboangiitis obliterans, diabetes-induced ischemia of extremity and takayasu arteritis. Cilostazol also be used as a complementary therapy after surgical treatment to help alleviate the symptoms, improve the circulation and inhibiting thrombosis in transplanted blood vessel.